IVF Outcomes: What May Help and Where Evidence Is Uncertain
Key Takeaways
Age, ovarian response, embryo development, and the couple's diagnosis guide IVF planning. Reviewing the previous cycle and treatment safety is more useful than automatically adding extras. Many add-ons lack convincing live-birth evidence; healthy habits support general health but cannot guarantee success.
Key evidence: ASRM: fertility evaluation (2021) ESHRE: ovarian stimulation (2025 update) ESHRE: add-on recommendations (2023)
Where to Start
After an unsuccessful IVF cycle, it is understandable to wonder whether one more test or treatment might have made the difference. Sometimes there is a useful change to make. Sometimes the cycle does not reveal a clear, treatable cause.
The starting point is a review of what happened, not a longer list of treatments. Here, “outcome” means the chance of a live birth as well as treatment safety. More eggs, better-looking embryos, or a positive pregnancy test are not the same outcome.
What Usually Matters Most
Age and Ovarian Reserve
When you use your own eggs, your age is an important predictor of IVF success. A blood test for anti-Müllerian hormone (AMH) and an ultrasound count of small ovarian follicles (antral follicle count) help estimate how the ovaries may respond to stimulation; they do not directly measure egg quality or tell you with certainty whether treatment will work. The ASRM fertility evaluation guidance recommends interpreting these tests alongside age, medical history, and previous response.
Embryo Development
Ask the team to explain the sequence: how many eggs were collected, how many were mature, how many fertilized, and how many embryos continued developing. This helps identify where a change might be worth discussing. It does not always reveal why a cycle failed. For a broader explanation, see the factors that influence IVF success.
The Uterus and Tubes
A finding on a scan is not automatically a reason for surgery. Fibroids that distort the cavity, polyps, and adhesions need individual assessment; the likely benefit of treatment depends on the finding and the clinical history. ASRM’s evaluation guidance supports a targeted assessment, not the same invasive tests for everyone.
A hydrosalpinx is different: it is a damaged, fluid-filled fallopian tube, not a problem inside the uterine cavity. For a hydrosalpinx communicating with the uterus, ASRM’s tubal surgery guidance supports discussing removal or blockage of the affected tube before IVF.
Male Factor
The semen analysis and the man’s medical history belong in the assessment too. ICSI, in which a single sperm is injected into an egg, can address certain fertilization problems, while surgical sperm retrieval is used for specific indications, such as some cases where no sperm are found in the ejaculate. These are not interchangeable ways to “boost” success; see the AUA/ASRM male infertility guideline.
Advanced sperm-selection methods also need separate consideration. For example, ESHRE’s add-on recommendations do not recommend routine PICSI (selection based on sperm binding to hyaluronic acid), IMSI (selection under high magnification), or magnetic sperm sorting. A laboratory improvement alone is not proof of more live births.
The Medical Steps Worth Reviewing
A useful plan explains both what is changing and why:
- Stimulation and safety: match the protocol to expected ovarian response and previous cycles, and plan how to reduce ovarian hyperstimulation syndrome (OHSS) risk. These are central topics in the ESHRE ovarian stimulation guideline, updated in 2025.
- Transfer timing: decide whether a fresh transfer is appropriate or whether freezing embryos and transferring later is safer or more suitable. The ESHRE ovarian stimulation guideline distinguishes reducing OHSS risk from improving cumulative live-birth rates: freezing all embryos is not automatically better for everyone.
- Transfer technique: ASRM guidance supports ultrasound guidance and soft catheters. Evidence about pregnancy rates should not be presented as a guaranteed live-birth benefit.
- Embryo number: discuss single-embryo transfer to reduce multiple-pregnancy risk, as addressed in the ESHRE embryo-transfer guideline. Reducing risk does not mean eliminating it.
When reviewing a previous IVF cycle, Dr. Senai Aksoy first looks at where difficulties arose: egg number, maturity, fertilization, embryo development, or implantation. His point is practical: changing a drug brand without examining the previous response is not, by itself, a new strategy. Even a well-reasoned plan cannot promise success.
Lifestyle: Helpful, but Not a Test of Willpower
General health and treatment safety matter. Ask for help with stopping smoking, and discuss alcohol and any supplements with the team. Ask the team to clarify any medication instructions you find difficult to follow. If an injection is missed or its timing is unclear, contact the clinic rather than changing the dose yourself.
Sleep, food, and activity deserve attention without becoming another source of pressure. A failed cycle is not evidence that you did not try hard enough.
Weight deserves a balanced conversation. ASRM’s obesity guidance notes that, in ovulatory women with obesity, weight-loss interventions before treatment have not been shown to improve live-birth rates after IVF. Health and anesthesia considerations still matter, but so does the possible cost of delaying treatment. There is no universal target weight or waiting period for every patient.
How to Evaluate an Add-on
An add-on is an extra test or treatment offered alongside standard IVF. ESHRE’s 2023 recommendations advise against routine endometrial scratching.
The same recommendations advise against immune treatments such as intralipid infusions and intravenous immunoglobulin (IVIG) as fertility add-ons. Evidence of benefit is lacking, and there are safety concerns. This recommendation concerns their use to improve fertility outcomes, not their use for a separate, diagnosed medical condition. If you already take an immune treatment for another condition, discuss it with your prescribing doctor; do not stop it yourself.
Before agreeing, ask:
- What problem in my case is this intended to address?
- Do studies in patients like me show more live births, or only a change in a laboratory measurement?
- What are the known risks, remaining uncertainties, cost, and possible delay?
- What would the plan be if I chose not to have it?
A recommendation should make sense without pressure to “try everything.” Read more about repeated IVF failure and the immune system.
At a Glance
| Decision | What to ask | What not to assume |
|---|---|---|
| Reviewing a previous cycle | At what stage did a difficulty arise, and could a change address it? | Every failed cycle has an identifiable, correctable cause |
| Adjusting treatment | Is the aim better response, safer treatment, or more live births? | These outcomes are interchangeable |
| Treating a uterine or tubal finding | What is the diagnosis and the evidence for treating it? | Every finding needs surgery |
| Changing lifestyle | What helps my health without an unhelpful delay? | Perfect habits can guarantee success |
| Adding an optional treatment | What is the evidence for this intervention in my situation? | More treatment means a better chance |
Related Reading
- What Most Influences IVF Success?
- Ways to Improve IVF Success: Evidence-Based Strategies
- IVF, ICSI, and Natural-Cycle IVF: Which Problem Each One Solves
- Repeated IVF Failure and the Immune System: What Is Actually Known?
FAQ
Is there one decisive trick to improve IVF success?
No. The useful next step depends on the diagnosis and what happened during treatment. Even after a careful review, there may be no clear explanation for a failed cycle.
Do IVF add-ons usually increase the chance of having a baby?
An add-on should be judged individually. Many lack convincing evidence of a live-birth benefit in routine use; a plausible theory or a better laboratory result is not enough.
Does lifestyle still matter during an IVF cycle?
Yes, for general health and treatment safety. It cannot guarantee pregnancy, and a failed cycle should not be blamed on imperfect habits.
What should take priority over optional extras?
Reviewing the diagnosis, previous response, relevant uterine or tubal findings, male factors, and the safety of the next plan.
How should patients evaluate a suggested add-on?
Ask about live-birth evidence in comparable patients, risks, cost, delay, and the option of proceeding without it.
Sources
- ASRM Practice Committee. Fertility evaluation of infertile women: a committee opinion. Fertility and Sterility. 2021;116(5):1255–1265. DOI: 10.1016/j.fertnstert.2021.08.038.
- ASRM Practice Committee. Performing the embryo transfer: a guideline. Fertility and Sterility. 2017;107(4):882–896. DOI: 10.1016/j.fertnstert.2017.01.025.
- ASRM Practice Committee. Role of tubal surgery in the era of assisted reproductive technology: a committee opinion. Fertility and Sterility. 2021;115(5):1143–1150. DOI: 10.1016/j.fertnstert.2021.01.051.
- ASRM Practice Committee. Obesity and reproduction: a committee opinion. Fertility and Sterility. 2021;116(5):1266–1285. DOI: 10.1016/j.fertnstert.2021.08.018.
- AUA/ASRM. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II. Fertility and Sterility. 2021;115(1):62–69. DOI: 10.1016/j.fertnstert.2020.11.016.
- ESHRE. Ovarian Stimulation for IVF/ICSI. 2025.
- ESHRE. Number of embryos to transfer during IVF/ICSI. 2023; summary paper 2024. Human Reproduction. DOI: 10.1093/humrep/deae010.
- ESHRE Add-ons working group. Good practice recommendations on add-ons in reproductive medicine. 2023. Human Reproduction. 38(11):2062–2104. DOI: 10.1093/humrep/dead184.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.